Patents by Inventor Annick DESJARDINS

Annick DESJARDINS has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11813298
    Abstract: Human clinical use of a chimeric poliovirus construct has demonstrated excellent anti-tumor effect. The mechanism of action is believed to involve both viral oncolysis as well as immune recruitment, both of which lead to necrosis in the area of the tumor. No adverse effects have been observed.
    Type: Grant
    Filed: July 5, 2022
    Date of Patent: November 14, 2023
    Assignee: Duke University
    Inventors: Matthias Gromeier, John H. Sampson, Darell D. Bigner, Annick Desjardins, Henry S. Friedman
  • Publication number: 20220339223
    Abstract: Human clinical use of a chimeric poliovirus construct has demonstrated excellent anti-tumor effect. The mechanism of action is believed to involve both viral oncolysis as well as immune recruitment, both of which lead to necrosis in the area of the tumor. No adverse effects have been observed.
    Type: Application
    Filed: July 5, 2022
    Publication date: October 27, 2022
    Inventors: Matthias Gromeier, John H. Sampson, Darell D. Bigner, Annick Desjardins, Henry S. Friedman
  • Patent number: 11406677
    Abstract: Human clinical use of a chimeric poliovirus construct has demonstrated excellent anti-tumor effect. The mechanism of action is believed to involve both viral oncolysis as well as immune recruitment, both of which lead to necrosis in the area of the tumor. No adverse effects have been observed.
    Type: Grant
    Filed: September 10, 2020
    Date of Patent: August 9, 2022
    Assignee: Duke University
    Inventors: Matthias Gromeier, John H. Sampson, Darell D. Bigner, Annick Desjardins, Henry S. Friedman
  • Publication number: 20210106633
    Abstract: Provided is a method of treating a tumor in an individual by neoadjuvant therapy, wherein the individual has not previously undergone treatment to effectively reduce tumor burden, the method comprising administering an oncolytic chimeric poliovirus construct, or an oncolytic chimeric poliovirus construct and an immune checkpoint inhibitor, followed by reduction of the tumor. The method may further comprise administration of immune checkpoint inhibitor or oncolytic chimeric poliovirus construct following reduction of tumor. Kits for performing the methods are also provided.
    Type: Application
    Filed: April 2, 2019
    Publication date: April 15, 2021
    Applicant: Duke University
    Inventors: Darell Bigner, Matthias Gromeier, Smita Nair, Henry Friedman, Annick Desjardins
  • Publication number: 20200405795
    Abstract: Human clinical use of a chimeric poliovirus construct has demonstrated excellent anti-tumor effect. The mechanism of action is believed to involve both viral oncolysis as well as immune recruitment, both of which lead to necrosis in the area of the tumor. No adverse effects have been observed.
    Type: Application
    Filed: September 10, 2020
    Publication date: December 31, 2020
    Applicant: Duke University
    Inventors: Matthias Gromeier, John H. Sampson, Darell D. Bigner, Annick Desjardins, Henry S. Friedman
  • Patent number: 10799543
    Abstract: Human clinical use of a chimeric poliovirus construct has demonstrated excellent anti-tumor effect. The mechanism of action is believed to involve both viral oncolysis as well as immune recruitment, both of which lead to necrosis in the area of the tumor. No adverse effects have been observed.
    Type: Grant
    Filed: July 9, 2019
    Date of Patent: October 13, 2020
    Assignee: Duke University
    Inventors: Matthias Gromeier, John H. Sampson, Darell D. Bigner, Annick Desjardins, Henry S. Friedman
  • Patent number: 10744171
    Abstract: Human clinical use of a chimeric poliovirus construct has demonstrated excellent anti-tumor effect. Sequential treatment with the virus construct followed by chemotherapy drugs increases the anti-tumor effect. Tumors of different types are susceptible to the combination treatment, including but not limited to melanoma, glioblastoma, renal cell carcinoma, prostate cancer, breast cancer, lung cancer, medulloblastoma, and colorectal cancer.
    Type: Grant
    Filed: March 20, 2017
    Date of Patent: August 18, 2020
    Assignee: Duke University
    Inventors: Darell D. Bigner, Matthias Gromeier, Annick Desjardins, Henry S. Friedman, Allan H. Friedman, John H. Sampson
  • Publication number: 20190343904
    Abstract: Human clinical use of a chimeric poliovirus construct has demonstrated excellent anti-tumor effect. The mechanism of action is believed to involve both viral oncolysis as well as immune recruitment, both of which lead to necrosis in the area of the tumor. No adverse effects have been observed.
    Type: Application
    Filed: July 9, 2019
    Publication date: November 14, 2019
    Applicant: Duke University
    Inventors: Matthias Gromeier, John H. Sampson, Darell D. Bigner, Annick Desjardins, Henry S. Friedman
  • Patent number: 10398743
    Abstract: Human clinical use of a chimeric poliovirus construct has demonstrated excellent anti-tumor effect. The mechanism of action is believed to involve both viral oncolysis as well as immune recruitment, both of which lead to necrosis in the area of the tumor. No adverse effects have been observed.
    Type: Grant
    Filed: February 9, 2017
    Date of Patent: September 3, 2019
    Assignee: Duke University
    Inventors: Matthias Gromeier, John H. Sampson, Darell D. Bigner, Annick Desjardins, Henry S. Friedman
  • Publication number: 20190105360
    Abstract: Human clinical use of a chimeric poliovirus construct has demonstrated excellent anti-tumor effect. Sequential treatment with the virus construct followed by chemotherapy drugs increases the anti-tumor effect. Tumors of different types are susceptible to the combination treatment, including but not limited to melanoma, glioblastoma, renal cell carcinoma, prostate cancer, breast cancer, lung cancer, medulloblastoma, and colorectal cancer.
    Type: Application
    Filed: March 20, 2017
    Publication date: April 11, 2019
    Applicant: Duke University
    Inventors: Darell D. Bigner, Matthias Gromeier, Annick Desjardins, Henry S. Friedman, Allan H. Friedman, John H. Sampson
  • Publication number: 20170216382
    Abstract: Human clinical use of a chimeric poliovirus construct has demonstrated excellent anti-tumor effect. The mechanism of action is believed to involve both viral oncolysis as well as immune recruitment, both of which lead to necrosis in the area of the tumor. No adverse effects have been observed.
    Type: Application
    Filed: February 9, 2017
    Publication date: August 3, 2017
    Applicant: Duke University
    Inventors: Matthias Gromeier, John H. Sampson, Darell D. Bigner, Annick Desjardins, Henry S. Friedman
  • Publication number: 20160030497
    Abstract: Human clinical use of a chimeric poliovirus construct has demonstrated excellent anti-tumor effect. The mechanism of action is believed to involve both viral oncolysis as well as immune recruitment, both of which lead to necrosis in the area of the tumor. No adverse effects have been observed.
    Type: Application
    Filed: November 21, 2013
    Publication date: February 4, 2016
    Inventors: Matthias GROMEIER, John H. SAMPSON, Darell D. BIGNER, Annick DESJARDINS, Henry S. FRIEDMAN